High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates

Journal of Medical Virology

Volumn 85, Issue 5, 2013, Pages 775-779

  Neumann Fraune, Maria ^a   Beggel, Bastian ^b   Pfister, Herbert ^a   Kaiser, Rolf ^a   Verheyen, Jens ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Co selection; HBsAg mutations; HBV drug resistance

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE;

ANTIVIRAL RESISTANCE; ARTICLE; DISEASE COURSE; HEPATITIS B VIRUS; HUMAN; NONHUMAN; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; STOP CODON; VIRUS MUTATION;

ADENINE; ANTIVIRAL AGENTS; CODON, NONSENSE; DRUG RESISTANCE, VIRAL; GENOTYPE; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MUTATION, MISSENSE; ORGANOPHOSPHONATES; RNA-DIRECTED DNA POLYMERASE;

HEPATITIS B VIRUS;

EID: 84875660318     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23530     Document Type: Article

References (20)

1. Amini-Bavil-Olyaee S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Luedde T, Trautwein C, Tacke F. 2009. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome. J Hepatol 51:647-654.
2. Amini-Bavil-Olyaee S, Vucur M, Luedde T, Trautwein C, Tacke F. 2010. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains. J Virol 84:1026-1033.
3. Andreone P, Gramenzi A, Cursaro C, Biselli M, Camma C, Trevisani F, Bernardi M. 2004. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 11:439-442.
4. Carman WF. 1997. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4:11-20.
5. Di Marco V, Di Stefano R, Ferraro D, Almasio PL, Bonura C, Giglio M, Parisi P, Cappello M, Alaimo G, Craxi A. 2005. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 10:431-439.
6. Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, Fraune M, Garcia A, Phillips RO. 2010. Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol 48:3223-3230.
7. Lacombe K, Boyd A, Gozlan J, Lavocat F, Girard PM, Zoulim F. 2010. Drug-resistant and immune-escape HBV mutants in HIV-infected hosts. Antivir Ther 15:493-497.
8. Lai MW, Yeh CT. 2008. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 13:875-879.
9. Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT. 2009. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 14:249-261.
10. Locarnini SA, Yuen L. 2010. Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther 15:451-461.
11. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, Holmes SP, Babrzadeh F, Gharizadeh B, Hanczaruk B, Simen BB, Egholm M, Shafer RW. 2009. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 199:1275-1285.
12. Rhee SY, Margeridon-Thermet S, Nguyen MH, Liu TF, Kagan RM, Beggel B, Verheyen J, Kaiser R, Shafer RW. 2010. Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res 88:269-275.
13. Schildgen O, Schewe CK, Vogel M, Däumer M, Kaiser R, Weitner L, Matz B, Rockstroh JK. 2004. Successfull therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. AIDS 18:2325-2327.
14. Svicher V, Gori C, Trignetti M, Visca M, Micheli V, Bernassola M, Salpini R, Gubertini G, Longo R, Niero F, Ceccherini-Silberstein F, De Sanctis GM, Spano A, Cappiello G, Perno CF. 2009. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 50:461-470.
15. Thai H, Campo DS, Lara J, Dimitrova Z, Ramachandran S, Xia G, Ganova-Raeva L, Teo CG, Lok A, Khudyakov Y. 2012. Convergence and coevolution of hepatitis B virus drug resistance. Nat Commun 3:789. DOI: 10.1038/ncomms1794.
16. Torresi J. 2002. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25:97-106.
17. Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, Bock TC. 2002. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299:88-99.
18. Warner N, Locarnini S. 2008. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 48:88-98.
19. Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC. 2011. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer 11:398.
20. Zoulim F, Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137:1593-1608; e1591-e1592.